SILVER SPRING, Md., Oct. 21, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2014 financial results before market open on Tuesday, October 28...
SILVER SPRING, Md., Aug. 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. District Court for the District of New Jersey has ruled in its favor in the company's case...
SILVER SPRING, Md., July 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2014."Our continued growth shows that our...
SILVER SPRING, Md., July 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2014 financial results before market open on Tuesday, July 29, 2014...
SILVER SPRING, Md., June 27, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the company's...
LA JOLLA, Calif. and SILVER SPRING, Md., May 6, 2014 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung...
SILVER SPRING, Md., April 29, 2014 /PRNewswire/ --Revenues of $289.4 millionNet income of $137.5 millionEarnings per Share of $2.73 per Basic Share or $2.43 per Diluted ShareNon-GAAP Earnings of $1.77 per Basic Share or...
SILVER SPRING, Md., April 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2014 financial results before market open on Tuesday, April 29...
26 Mar 2014
Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin
SILVER SPRING, Md., March 26, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan'sMinistry of Health, Labour and Welfare has granted approval for Remodulin® (treprostinil)...
25 Feb 2014
United Therapeutics Corporation Reports 2013 Fourth Quarter And Annual Financial Results
SILVER SPRING, Md., Feb. 25, 2014 /PRNewswire/ -- Total Annual Revenues of $1.1 billionAnnual Earnings per Share of $3.49 per Basic Share or $3.28 per Diluted ShareAnnual Non-GAAP Earnings of $10.88 per Basic Share or...
SILVER SPRING, Md., Feb. 18, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2013 financial results before market open on Tuesday...
SILVER SPRING, Md., Dec. 20, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved Orenitram (treprostinil)...